COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

NCL News Archive

Monday, April 13, 2020

Immunology Webinar Series

UPDATE--The online Immunology Workshop originally planned for June 8-12 and 15-18, 2020 has been reschdeuled to May 18-22, 25-28, 2020. The meeting time (11am-1pm EDT) and workshop agenda remain unchanged.  

FREE Online Immunology Workshop

Molecular and Cellular Immunology: From Basics to Applications in Preclinical... View Post

Monday, March 30, 2020

Nanotechnology Resources & Needs

The NCL is collecting feedback....Please take this brief survey so that we can stay at the forefront of your nanotechnology needs. The survey should take just a few minutes and will help the NCL better understand the curent and future demands of the nanotechnology research community. We appreciate your feedback! View Post

Thursday, March 26, 2020

Bioequivalence Studies: Doxil vs Sun Pharma and Abraxane vs Genexol-PM

The NCL recently completed a 2.5 year interagency collaboration with the US Food and Drug Administration (FDA) to evaluate the bioequivalence of marketed nanomedicines. The complexity of nanomedicine drug formulations poses unique scientific challenges. And, with the influx of generic versions of several nanomedicines now nearing clinical evaluation, these formulations pose unique regulatory... View Post

Monday, March 9, 2020

New Assay Cascade Awardees Announced

The NCL solicits applications for the most promising cancer nanomedicine candidates for acceptance into its Assay Cascade characterization and testing program. Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety,... View Post

Tuesday, February 25, 2020

New Funding Opportunity

Toward Translation of Nanotechnology Cancer Interventions (TTNCI), PAR-20-116

The National Cancer Institute has just posted a new funding opportunity entitled "Toward Translation of Cancer Nanotechnology Interventions (TTNCI)". TTNCI is meant to enable the translation of nanotechnology-based cancer interventions relying on next-generation nanoparticle formulations and/... View Post

Friday, February 7, 2020

Career Opportunities - 1 Immediate Opening

The NCL has 1 immediate opening. This is an opportunity to be part of a multidisciplinary team and contribute to the National Mission of the only NIH-sponsored U.S. National Lab. You will develop your skills working on state of the art strategies for drug delivery from the pipelines of global pharma and biotech companies. A brief descriptions of the opening is posted below.... View Post

Wednesday, February 5, 2020

Upcoming Application Deadline - March 2, 2020

The next deadline for application to NCL’s Assay Cascade characterization program is March 2, 2020. Visit our application and instructions page to download the template and review the evaluation criteria:

Have questions about the application, evaluation criteria, or the overall process? Please... View Post

Wednesday, October 16, 2019

NCL Leadership Changes

The NCL is proud to announce the appointment of Drs. Marina Dobrovolskaia and Stephan Stern as Laboratory Co-Directors. Dr. Dobrovolskaia will serve as Director of Operations for the lab, and Dr. Stern will serve as Director of Research & Development for the lab.

NCL will continue to support nanotech developers in their translational efforts by offering characterization and... View Post

Wednesday, October 16, 2019

NCL Assay Cascade—Back to Quarterly Application Deadlines

By popular request, the NCL will revert back to quarterly deadlines for the NCL’s Assay Cascade characterization service. The quarterly deadlines will be the first business days of March, June, September and December. The next application deadline will be December 2, 2019. For questions on the application process, email us at

Wednesday, October 16, 2019

Funding Opportunities & Translational Resources

The National Cancer Institute’s Nanodelivery Systems and Devices Branch has compiled the following list of funding opportunities and translational resources that may be of interest to nanotech developers. Click the link for each announcement to learn more.

Alliance IRCN:

PAR 17-240 – Innovative Research in Cancer Nanotechnology (R01).  The... View Post